

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510



SECRETARY OF THE SENATE

00 AUG 15 AM 9:43

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Steelman Health Strategies	
2. Address <input checked="" type="checkbox"/> Check if different than previously reported 555 12th Street, N.W. Washington Suite 1230 DC 20004	
3. Principal Place of Business (if different from line 2) City State/Zip (or Country)	
4. Contact Name Layna McConkey	Telephone Email (optional) 5. Senate ID # 36617-137
7. Client Name <input type="checkbox"/> Self Pharmaceutical Research & Manufacturers of America	6. House ID # 31914-009

TYPE OF REPORT 8. Year 2000 Midyear (January 1-June 30) OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report >> Termination Date _____

11. No Lobbying Activity

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13	
12. Lobbying Firms	13. Organizations
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying activities for this reporting period were:
Less than \$10,000 <input type="checkbox"/>	Less than \$10,000 <input type="checkbox"/>
\$10,000 or more <input checked="" type="checkbox"/> >> \$ <u>5100,000.00</u> Income (nearest \$20,000)	\$10,000 or more <input type="checkbox"/> >> \$ _____ Expenses (nearest \$20,000)
Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options. <input type="checkbox"/> Method A. Reporting amounts using LIDA definitions only <input type="checkbox"/> Method B. Reporting amounts under section 6053(b)(8) of the Internal Revenue Code <input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Signature

Date 07/28/2000

Printed Name and Title Deborah Steelman - Esquire

Page 1 of 5

Registrant Name: Steelman Health Strategies

Client Name: Pharmaceutical Research & Manufacturers of America

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

- 15. General issue area code MMM (one per page)
- 16. Specific Lobbying issues
**S.578, Health Care PIN Act,
S.881, Medical Information Protection Act of 1999,
H.R.1885, International Prescription Drug Parity Act,
H.R.1495, Access to Prescription Medications in Medicare Act of 1999,
S.841, Access to Rx Medications in Medicare Act of 1999,
S.731, Prescription Drug Fairness for Seniors Act of 1999,
H.R.664, Prescription Drug Fairness for Seniors Act of 1999,
S. 2464, Prescription Drug Fairness Act,
S. 1895, Medicare Preservation and Improvement Act of 1999,
H.R. 4680, Medicare Rx 2000 Act,**

17. House(s) of Congress and Federal agencies contacted Check if None
**Department of Health & Human Services
Executive Office of the President
House of Representatives
Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Steelman, Deborah		No
Coughlin, Shawn		No
Jennaing, Steve		No
McConkey, Larva		No

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 07/29/2006

Printed Name and Title Deborah Steelman - Esquire Page 2 of 5

Registrant Name: **Steelman Health Strategies**

Client Name: **Pharmaceutical Research & Manufacturers of America**

Item	Description	Data
16	Lobbying Issues	Implementation of the Balanced Budget Act of 1997 Implementation of the Health Insurance Protection and Portability Act of 1996 Implementation of the Balanced Budget Refinement Act of 1999

Registrant Name: **Steelman Health Strategies**

Client Name: **Pharmaceutical Research & Manufacturers of America**

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code **PHA** (one per page)

16. Specific Lobbying Issues
**S.578, Health Care PIN Act,
S.891, Medical Information Protection Act of 1999,
H.R.1885, International Prescription Drug Parity Act,
H.R.1495, Access to Prescription Medications in Medicare Act of 1999,
S.841, Access to Rx Medications in Medicare Act of 1999,
S.731, Prescription Drug Fairness for Seniors Act of 1999,
H.R.664, Prescription Drug Fairness for Seniors Act of 1999,
S. 2464, Prescription Drug Fairness Act,
S. 1895, Medicare Preservation and Improvement Act of 1999,
H.R.4680, Medicare Rx 2000 Act,**

17. House(s) of Congress and Federal agencies contacted
**Department of Health & Human Services
Executive Office of the President
House of Representatives
Senate**

Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Steelman, Deborah		No
Coughlin, Shawn		No
Jenning, Steve		No
McConkey, Layna		No

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature _____

Date **07/28/2000**

Printed Name and Title **Deborah Steelman - Esquire**

Page **4** of **5**

Registrant Name: Steelman Health Strategies

Client Name: Pharmaceutical Research & Manufacturers of America

Item	Description	Data
16	Lobbying Issues	Implementation of the Balanced Budget Act of 1997 Implementation of the Health Insurance Protection and Portability Act of 1996 Implementation of the Balanced Budget Refinement Act of 1999